Adaptive Optics Imaging for Outer Retinal Diseases

This observational study is using advanced imaging techniques called adaptive optics (AO) to take very detailed pictures of the back of your eye. The goal is to better understand outer retinal diseases like Age-Related Macular Degeneration and Retinitis Pigmentosa. Researchers hope to develop new ways to diagnose these conditions and track how they change over time. You may be able to join if you are 21 or older, can follow instructions during an eye exam, and can sign an informed consent form. The study is looking at the density of photoreceptor cells and retinal pigment epithelial (RPE) cells, and how RPE cell parts move. The current recruitment status is unclear.

Study design
This is an observational study planning to enroll up to 100 participants, including healthy volunteers and those with outer retinal diseases. It is a longitudinal study, meaning participants will be followed over time.
What's involved
You would undergo adaptive optics imaging sessions where high-resolution videos of your retinal cells are collected. For some measurements, imaging may be repeated three times over 1-2 weeks.
Compensation
Not stated in the trial record.
Follow-up
Photoreceptor and RPE cell densities will be calculated once at an imaging session. RPE organelle motility will be quantified three times, separated by 1-2 weeks, for reproducibility.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05355415

Adaptive Optics Imaging of Outer Retinal Diseases

Recruiting
Not specifiedAges 21+Observational
Food and Drug Administration (FDA)
~100 participants
Updated 2026-05-08 on ClinicalTrials.gov
What's tested:Adaptive optics imaging

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Photoreceptor (PR) density
Measured over PR density will be calculated once at the AO imaging session in which PRs are the target.
+3 more outcomes measured
Retinal Degeneration
Age-Related Macular Degeneration
Retinitis Pigmentosa
Hydroxychloroquine Retinopathy
Usher Syndromes
Late-Onset Retinal Degeneration
Cone Dystrophy
Cone Rod Dystrophy
Rod Cone Dystrophy
Rod Dystrophy
2 sites across 1 states
Maryland2
  • Daniel X Hammer, Ph.D. · PRINCIPAL_INVESTIGATOR · Food and Drug Administration (FDA)

Opens a ready-to-send draft in your own email app — review before sending.

  • Photoreceptor (PR) densityPR density will be calculated once at the AO imaging session in which PRs are the target.

    PR density will be calculated at specific retinal eccentricities from cells counted in average AO-OCT volumes or average AOSLO frames.

  • Retinal pigment epithelial (RPE) cell densityRPE cell density will be calculated once at the AO imaging session in which RPE cells are the target.

    RPE cell density will be calculated at specific retinal eccentricities from cells counted in average AO-OCT volumes.

  • RPE cell organelle motilityRPE motility will be calculated once at the AO imaging session in which RPE cells are the target. For the reproducibility portion of the study, RPE organelle motility will be quantified three times separated by 1-2 weeks.

    RPE cell organelle motility will be calculated from the decorrelation time constant for cells segmented from a sequence of AO-OCT volumes.

  • PR cell functionPR function will be calculated once at the AO imaging session in which PR cells are stimulated. For the reproducibility portion of the study, PR cell function will be quantified three times separated by 1-2 weeks.

    Photoreceptor cell (cone) function will be measured from phase changes between inner segment - outer segment junction and cone outer segment tip signals in a sequence of AO-OCT volumes collected during visible light stimulation.